GSK's Triple Combo COPD Drug Gets Europe Okay
Europe's regulators have followed their US counterparts and given the green light to GSK's Trelegy. Now the company is hoping that having the first once-daily single inhaler triple therapy for COPD will boost its respiratory business.
You may also be interested in...
AstraZeneca’s respiratory chief tells Scrip Japan’s approval of the triple-combination inhaled therapy is both a milestone for treating COPD and for the UK pharma’s strategy.
The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.
Turnover at the German group's pharma unit has been hit harder than forecast by the coronavirus pandemic and hefty price cuts linked to China's drug procurement policy but Bayer remains upbeat.